Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 799 of 1,261
  1. US 8802695

    Apoptosis signal-regulating kinase 1 inhibitors

    Takeda Pharmaceutical Company Limited · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted
  2. US 8802836

    Cloning and recombinant productions of Vespula venom protease and methods of use thereof

    PLS-Design GmbH · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted
  3. US 8802644

    Lipid formulation

    Tekmira Pharmaceuticals Corporation · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted
  4. US 8802628

    Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration

    IRONWOOD PHARMACEUTICALS, INC. · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted
  5. US 8802633

    Autophagy-inducing peptide analogs

    The Board of Regents of the University of Texas System · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted
  6. US 8802656

    Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same

    The Board of Regents of the University of Texas System · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted
  7. US 8802107

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted
  8. WO 2014117863

    FORMES POLYMORPHES DE SELS D'ADDITION D'ACIDE DE THIOXANTHÈNE-9-YLIDÈNE-1-MÉTHYLPIPÉRIDINES UTILISÉS COMME COMPOSÉS ANTIMIGRAINEUX

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Aug 7, 2014 · Expires Aug 2, 2034

    granted
  9. US 8796233

    Methods and systems for modulating hormones and related methods, agents and compositions

    The Regents of the University of California · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  10. US 8796302

    Methods related to the treatment of neurodegenerative and inflammatory conditions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  11. US 8796270

    N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor

    GILEAD CONNECTICUT, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  12. US 8796291

    A3 adenosine receptor antagonists and partial agonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  13. US 8796322

    Methods for using 1,2,4-oxadiazole benzoic acid compounds

    PTC THERAPEUTICS, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  14. US 8796327

    Method for inhibiting production of cytokines of T helper cell type II and/or inhibiting production of chemokines using brazilin

    China Medical University · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  15. US 8795669

    Stabilized formulations containing anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  16. US 8796320

    1,3,4-Oxadiazole-2-carboxamide compound

    Pharmadesign, Inc. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  17. US 8796436

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  18. US 8796444

    Methods and compositions for the specific inhibition of gene expression by double-stranded RNA

    INTEGRATED DNA TECHNOLOGIES, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  19. US 8796453

    Processes and intermediates for producing azaindoles

    Vertex Pharmaceuticals Incorporated · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  20. US 8796435

    Modular functional peptides for the intracellular delivery of nanoparticles

    United States of America as represented by the Secretary of the Air Force · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  21. US 8796254

    Methods for using carboxamide, sulfonamide and amine compounds

    Rigel Pharmaceuticals, Inc. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  22. US 8795650

    Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells

    The Regents of the University of California · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  23. US 8796022

    Generation of functional basal forebrain cholinergic neurons from stem cells

    Northwestern University · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  24. US 8796008

    Influenza A virus vaccines and inhibitors

    The Board of Regents of the University of Texas System · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.